Clinicians should try to incorporate biomarker data in their diagnosis of patients with Alzheimer's disease or conditions potentially leading to it, an ad hoc expert panel recommended.
Levels of beta-amyloid or tau proteins in cerebrospinal fluid (CSF), or data from MRI or PET scans using amyloid-specific tracers, should be part of the differential diagnosis of Alzheimer-related disorders, according to two dozen members of the International Working Group for New Research Criteria for the Diagnosis of Alzheimer's Disease.
Led by Bruno Dubois, MD, of Salpetriere Hospital in Paris, the group also put forth what it called a "lexicon" to standardize the taxonomy of Alzheimer-related conditions.
Their recommendations, which would give biomarkers a more prominent role in clinical practice than suggested this summer by a U.S.-based working group, appeared online in Lancet Neurology.
Full Article
No comments:
Post a Comment